Articles related to HODGKIN LYMPHOMA (HL)

With a complete metabolic response rate of 82.1% after just four cycles of induction, this new regimen could change how we approach treatment for young patients with low risk, relapsed classical Hodgkin lymphoma.

FIL-ROUGE trial data presented at the International Conference on Malignant Lymphoma 2023 highlight the potential of intensified ABVD in improving outcomes for untreated Hodgkin lymphoma patients. Further exploration of this regimen’s long-term toxicity is anticipated.

The approval for the treatment of pediatric patients aged 2 years and older with previously untreated high-risk classic Hodgkin lymphoma (HL) was based on the AHOD1331 phase 3 study, which examined the effects of brentuximab vedotin (Adcetris, Seagen) in combination with the dose-intensive chemotherapy regimen AVE-PC (doxorubicin, vincristine, etoposide, prednisone, and cyclophosphamide). Results showed that patients who received the AVE-PC combination had better event-free survival than those who received ABVE-PC (doxorubicin, bleomycin, vincristine, etoposide, prednisone and cyclophosphamide). Patients experienced a 59% decrease in their risk of death, second cancer, or disease progression.

After receiving a recently confirmed diagnosis of early-stage nodular sclerosing Hodgkin lymphoma, a 27-year-old woman is evaluated. She has not experienced weight loss, night sweats, or fever. She has an unremarkable medical history and doesn’t use any drugs. What is the best course of action after a physical examination, lab tests, and scans?

According to the researchers, “The findings from this study suggest that survivors of [HL] require life-long regular screening for early detection of chronic health conditions and that healthy lifestyle behaviors need to be strongly encouraged as these survivors appear more vulnerable to neurocognitive and psychosocial sequelae from these events.”

The authors of this JCO study used a PET-adaptive approach to reduce the need for radiotherapy (RT) in early PET (-) disease and escalate therapy in patients with PET (+) disease. The study reports excellent outcomes for the approach, which allowed omission of radiotherapy in more than three-quarters of patients.